Secretion of anti-inflammatory cytokines

The "Secretion of anti-inflammatory cytokines" refers to the production and release of immunoregulatory proteins—such as IL-10, TGF-β, IL-4, IL-13, IL-11, and IL-1RA—by immune cells like M2 macrophages, T helper 2 (Th2) cells, and others, to counteract and limit pro-inflammatory responses[2][5]. These cytokines modulate inflammation by suppressing the activity of antigen-presenting cells, inhibiting synthesis of pro-inflammatory cytokines (e.g., IL-12, IL-23), and promoting tissue repair and resolution of inflammation[1]. Dysregulation of this process can contribute to chronic inflammatory diseases, autoimmunity, or increased susceptibility to infections. While individual cytokines such as IL-10 or TGF-β are well-defined molecular entities, "Secretion of anti-inflammatory cytokines" is a biological process, not a single molecular target. Thus, it is not classified as a therapeutic target in the traditional sense (e.g., receptor, enzyme, transporter), and no drugs directly target this process as a whole. Rather, drugs and biologics may target specific anti-inflammatory cytokines or their receptors (e.g., recombinant IL-10, anti-IL-10 antibodies, TGF-β inhibitors)[2][5]. Biomarkers for monitoring include circulating levels of IL-10, TGF-β, and other anti-inflammatory cytokines, which may indicate the balance or imbalance of the immune response. Safety concerns primarily relate to the risk of over-suppression of immune responses, leading to impaired pathogen clearance and susceptibility to infections.

Other names

Anti-inflammatory cytokine releaseAnti-inflammatory cytokine production